STAYBLE THERAPEUTICS NASDAQ FIRST NORTH
We are currently taking the next step in our exciting journey towards an injection-based treatment for chronic low back pain. With a completed clinical phase 1b study, STA363 is one step closer to the market.Investor Relations
Latest press releases
Stayble receives approval from regulatory authorities to start clinical phase 2b study in The Netherlands
Stayble announces today, March 17 2020, that the Dutch regulatory authorities (RA) have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The approval from...
Stayble has submitted applications to regulatory authorities in Spain for start of the Phase 2b clinical trial.
The company can announce that an additional important step for starting the phase 2b clinical trial during Q2 has been completed. The company has submitted applications to regulatory authorities in Sp...
IPO DOCUMENTATIONRead more
Get all the latest news
Bridging the therapeutic gap
About 30% of all patients with discogenic cLBP are helped by therapy such as analgesics and physiotherapy, and only 1% undergo spine surgery. Stayble’s product STA363 will bridge the gap between conservative and radical therapy to the benefit of millions of patients presently left on their own to cope with sustained and disabling pain.Our market
Treating the root cause of the disease. Not just the symptoms.
Instead of costly or time-consuming procedures, such as spinal fusion or long-term physiotherapy, our cLBP treatment is an easily performed, single injection procedure that stabilises the disc by transforming it to connective tissue. Unlike any other currently available treatment, this has the potential to permanently attenuate the pain significantly faster than surgical intervention.
An intervertebral disc consists of two main parts: the disc centre and the wall. The disc centre consists largely of a highly hydrated gel together with nucleus pulposus cells and fibroblasts.
DEGENERATED UNTREATED DISC
When a disc degenerates it becomes less stable and proinflammatory substances formed during the degenerative process can leak from the inner core of the disc. Pain-sensing nerves within and outside the wall of the disc are activated. These processes cause back pain.
By injecting STA363 directly into the degenerated intervertebral disc, the cells are triggered to produce collagen and the damaged disc is transformed into connective tissue. This helps restabilise the intervertebral segment and reduces leakage of proinflammatory substances.
Get in touch
We are always looking for passionate people who are interested in joining us to help realizing our vision. Please leave your contact details and we will get back to you email@example.com